Eckert & Ziegler Receives Production Authorization for Thorium and Lutetium Compounds

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Essential phrase(s): Miscellaneous
09.08.2021 / 14:23
The issuer is only liable for the information of this announcement.

Berlin, August 9, 2021. Eckert & Ziegler Radiopharma GmbH in Braunschweig, a subsidiary of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX), has now received production authorization from the Decrease Saxony authorities for numerous thorium and lutetium compounds in accordance with the German Medications Act. This authorization enables Eckert & Ziegler to offer its customers in the pharmaceutical market with therapeutic radioisotopes for medical trials and beyond. The radioisotopes are the central active substances in a sequence of revolutionary most cancers medication that are presently getting analyzed in sophisticated phases by a lot of drug producers.

Acquiring the manufacturing authorization also entitles the Eckert & Ziegler Group to milestone payments for profitable technologies developments. The earnings from these milestones, nonetheless, have currently been accounted for in the recently current steerage for 2021.

“Owing to the large number of studies in which lutetium-177 is remaining clinically analyzed throughout the world, we anticipate an escalating need for this isotope and similar expert services in the coming yrs. With the new technological know-how and output facilities in Europe, Asia, and North America, we see ourselves as remaining excellently positioned to satisfy this demand,” stated Dr. Lutz Helmke, member of the Govt Board of Eckert & Ziegler AG.

Radiotherapeutic agents that are coupled with lutetium-177 prior to injection are at present beneath advancement for quite a few sorts of cancer. Lutetium-177-based medicine for the cure of metastatic prostate cancer are already in the medical period III trials. Therapeutic agents for other tumor kinds are also awaiting acceptance. In addition to its effectiveness, the edge of lutetium therapy is that it can be coupled with quite exact diagnostics. The provider material of the therapeutic agent can be connected to a diagnostic radioisotope, for case in point gallium-68. Applying distinctive equipment, so-known as PET scanners, the reaction price for the affected person and hence the usefulness of treatment method can be predicted with significant precision in progress.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with much more than 800 workers is a major specialist for isotope-similar elements in nuclear drugs and radiation treatment. The business offers a broad range of expert services and products for the radiopharmaceutical market, from early enhancement perform to contract producing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are shown in the TecDAX index of Deutsche Börse.
Contributing to conserving life.

Your make contact with:
Eckert & Ziegler AG, Karolin Riehle, Trader Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 () 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

09.08.2021 Dissemination of a Company Information, transmitted by DGAP – a support of EQS Team AG.
The issuer is only accountable for the content material of this announcement.

The DGAP Distribution Solutions include things like Regulatory Announcements, Economic/Corporate Information and Push Releases.
Archive at www.dgap.de